Application of indole-3-lactic acid in preparation of medicine for preventing or treating osteoporosis

By using indole-3-lactic acid as the active ingredient of the drug and constructing engineered bacteria that metabolize ILA, the treatment problem of osteoporosis caused by chemotherapy has been solved, significantly improved bone density and inhibited osteoclast differentiation, and provided osteoporosis new treatment options.

CN118903112APending Publication Date: 2024-11-08ZHEJIANG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411157679.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The application of indole-3-lactic acid in the prevention or treatment of osteoporosis has not been explored in the prior art, especially in osteoporosis caused by chemotherapy.

Method used

Indole-3-lactic acid (ILA) is used as the active ingredient of the drug, and provides drugs to prevent or treat osteoporosis through oral administration, and by constructing an engineered bacteria E.c-ldhA bacteria that can metabolize and synthesize ILA, inhibiting osteoclasting Cell formation and differentiation.

Benefits of technology

By significantly increasing the bone mineral density, bone volume fraction and trabecular number, inhibiting the formation of osteoclasts and downregulating the expression of related genes, it proves that ILA has a preventive and therapeutic effect on osteoporosis, providing new therapeutic ideas.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903112A_ABST
    Figure CN118903112A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of biological medicines, and relates to application of indole-3-lactic acid (ILA) in preparation of medicines for preventing or treating osteoporosis. Through intragastric administration of ILA to mice, it is found that ILA can significantly inhibit osteoporosis of mice. Meanwhile, in-vitro experiments find that the ILA can inhibit osteoclast differentiation. An ldhA gene capable of synthesizing ILA protein is overexpressed in escherichia coli, and an E.c-ldhA engineering bacterium is constructed. The E.c-ldhA engineering bacteria are fed into the stomach of a mouse, and the result shows that the E.c-ldhA engineering bacteria can significantly inhibit the osteoporosis of the mouse. RNA-seq detection finds that ILA can inhibit activation of an osteoclast differentiation pathway induced by RANKL + M-CSF by down-regulating expression of genes such as Ctsk, Acp5, Dcstamp, Oscar and Calcr, so as to block formation of osteoclasts. Therefore, the E.c-ldhA engineering bacterium and the metabolite ILA thereof can inhibit osteoclast differentiation and relieve osteoporosis, and a new diagnosis and treatment direction and strategy are provided for prevention and treatment of osteoporosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the application of indole-3-lactic acid (ILA) in the preparation of medicines for preventing or treating osteoporosis. Background Art

[0002] Osteoporosis (OP) is a systemic progressive bone disease characterized by low bone mass, damage to bone tissue microstructure, increased bone fragility, and easy fractures. Osteoporosis is common in postmenopausal women and the elderly. With the increasing aging of the population, osteoporosis has gradually become a serious public health problem due to its high incidence, high disability rate, high mortality rate and low quality of life, threatening the health and life of middle-aged and elderly people and placing a heavy burden on families and society. However, although people have gradually realized the negative impact that osteoporosis may bring, high-risk groups are still generally not fully diagnosed and properly prevented and treated, and compared with cancer or cardiovascular risks, osteoporosis may often be ignored even if it is discovered. Therefore, paying attention to the prevention and treatment of osteoporosis is of great significance to protecting the health of the middle-aged and elderly population.

[0003] The imbalance of bone homeostasis maintained by bone formation dominated by osteoblasts and bone resorption dominated by osteoclasts is one of the important causes of osteoporosis. Osteoblasts and osteoclasts are two different types of cells in bone tissue, which play an important role in the formation and remodeling of bones. Osteoblasts are responsible for synthesizing and secreting bone matrix (including collagen and other proteins required for bone tissue), promoting bone mineralization, that is, depositing inorganic salts such as calcium and phosphorus into the bone matrix, making bones hard and strong, which is essential for maintaining bone growth, repair and bone density. Osteoclasts have the ability to decompose and absorb bone tissue, and play an important role in bone remodeling and repair. They can dissolve bone matrix by secreting acidic substances and enzymes, engulf bone tissue fragments, and form bone resorption pits. Osteoclasts maintain the renewal and remodeling of bone tissue by regulating the bone remodeling process (bone density and morphology). In the normal human body, bone is constantly absorbed by osteoclasts and replaced by new bone formed by osteoblasts. The balance between the two and the regulation of these processes are essential for maintaining bone density and mineral homeostasis under healthy conditions. Osteoporosis occurs due to the imbalance of bone absorption exceeding bone formation during bone remodeling. The dynamic balance of osteoclasts and osteoblasts is affected by a variety of internal and external factors, such as genetics, age, gender, lifestyle, diet, intestinal flora, and bacterial metabolites.

[0004] Indole-3-lactic acid (ILA) is a bacterial-derived bioactive compound that can be produced by the ldhA protein of intestinal microorganisms through the tryptophan metabolic pathway. ILA has multiple biological effects. ILA can help maintain the health of the intestine and its microbial balance by promoting the growth of beneficial bacteria, such as lactic acid bacteria and bifidobacteria, and inhibiting the growth of harmful bacteria. This is essential for the normal function of the digestive system and the health of the immune system. ILA improves the intestinal barrier function, reduces the invasion of harmful substances into the intestine, and improves the body's immune capacity. At the same time, ILA has the ability to regulate the activity of immune cells, balance immune responses, and inhibit inflammatory responses, which makes it potentially valuable in the treatment and management of immune-related diseases such as autoimmune diseases, allergic diseases, and inflammatory diseases. In addition, ILA can promote the growth and development of nerve cells and improve brain nerve function. ILA also plays an important role in inhibiting the growth and spread of tumor cells. In general, ILA is a compound with multiple biological activities that plays an important role in intestinal health, immune regulation, nervous system function, and anti-tumor. However, there are currently no reports on the biological phenotypes associated with ILA and osteoporosis. Summary of the invention

[0005] In order to solve the deficiencies in the prior art, the present invention aims to provide the use of indole-3-lactic acid in preventing or treating osteoporosis.

[0006] The specific technical solutions of the present invention are as follows:

[0007] In a first aspect, the present invention provides use of ILA in preparing a drug for preventing or treating osteoporosis.

[0008] Furthermore, the invention is particularly used in the preparation of medicines for improving osteoporosis caused by chemotherapy. The osteoporosis caused by chemotherapy includes but is not limited to osteoporosis caused by chemotherapy drugs such as cyclophosphamide.

[0009] In a second aspect, the present invention provides use of ILA in preparing osteoclast inhibitors.

[0010] In a third aspect, the present invention provides the use of an engineered bacterium (such as Ec-ldhA bacteria) capable of metabolizing and synthesizing ILA in the preparation of a drug for preventing or treating osteoporosis.

[0011] Furthermore, the invention is particularly used in the preparation of medicines for improving osteoporosis caused by chemotherapy. The osteoporosis caused by chemotherapy includes but is not limited to osteoporosis caused by chemotherapy drugs such as cyclophosphamide.

[0012] Furthermore, the Ec-ldhA bacteria are obtained by cloning the full-length DNA fragment of the ldhA gene (SEQ ID NO: 1) into the pRSFDuet vector using standard molecular cloning technology, and then introducing the full-length DNA fragment into the E. coli bacteria to obtain the Ec-ldhA engineered bacteria.

[0013] In a fourth aspect, the present invention provides use of Ec-ldhA bacteria in the preparation of osteoclast inhibitors.

[0014] In addition, for any drug or inhibitor in the above applications, ILA can be the only active ingredient in the drug or inhibitor.

[0015] The administration method of any drug or inhibitor in the above application is oral administration.

[0016] Any drug or inhibitor in the above applications may contain carriers and / or excipients acceptable in the corresponding field; its dosage form may be pills, tablets, powders, capsules, granules, suspensions, injections, oral solutions, enemas or tube feeding preparations, etc.

[0017] The present invention has at least the following advantages and beneficial effects:

[0018] The present invention has proved through animal experimental studies that oral ILA can significantly increase bone mineral density, bone volume fraction, bone surface area to tissue volume ratio and trabecular number, significantly alleviate the increase of trabecular separation, and at the same time, can significantly inhibit the formation of osteoclasts, and inhibit osteoclast differentiation pathways by down-regulating the expression of Ctsk, Acp5, Dcstamp, Oscar and Calcr genes, proving that ILA has preventive and therapeutic effects on osteoporosis. In addition, the present invention constructs an engineered bacterium Ec-ldhA bacteria that can metabolize and synthesize ILA, and experimentally verifies that it also has a significant effect on improving osteoporosis. The present invention can provide new clues and new ideas for the treatment of osteoporosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1: The effect of ILA in Example 1 in inhibiting osteoporosis in mice. In the figure, A is the mass spectrometry detection result of ILA content in mouse femoral bone marrow. BD are the 3D reconstruction results of MicroCT scans of femoral samples of mice in the control group (CTL group), CTX group and CTX+ILA group, respectively. E is the statistical results of bone mineral density (BMD), bone volume fraction (BV / TV), bone surface area to tissue volume ratio (BS / TV), trabecular number (Tb.N) and trabecular separation (Tb.Sp) of mouse femur. FH are the TRAP staining results of femurs of mice in the control group (CTL group), CTX group and CTX+ILA group, respectively. I is the ELISA detection result of β-CTX in mouse serum. ns, p>0.05; *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.

[0020] Figure 2 The effects of ILA and IPA (indole-3-propionic acid) on osteoclast differentiation in Example 2. A and B are the TRAP staining results of the control group (CTL group) and the RANKL group, respectively. CE are the effects of different concentrations (100 μM, 200 μM and 500 μM) of ILA on RANKL-induced mouse osteoclast differentiation, and FH are the effects of different concentrations (100 μM, 200 μM and 500 μM) of IPA on RANKL-induced mouse osteoclast differentiation. Magnification: 20×.

[0021] Figure 3 3 is the role of ldhA in inhibiting osteoporosis in mice. A is the mass spectrometry detection result of ILA content in mouse femoral bone marrow. BD are the 3D reconstruction results of MicroCT scans of femoral samples of mice in the control group (CTL group), CTX group and CTX+Ec-ldhA group, respectively. E is the statistical results of bone mineral density (BMD), bone volume fraction (BV / TV), bone surface area to tissue volume ratio (BS / TV), trabecular number (Tb.N) and trabecular separation (Tb.Sp) of mouse femur. FH are the TRAP staining results of femurs of mice in the control group (CTL group), CTX group and CTX+Ec-ldhA group, respectively. I is the ELISA detection result of β-CTX in mouse serum. ns, p>0.05; *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.

[0022] Figure 4: The inhibitory effect of ILA on the RANKL+M-CSF-induced osteoclast differentiation pathway in Example 4. A is the KEGG pathway enrichment analysis result of the RANKL+ILA group vs the RANKL group. B is the expression changes of Ctsk, Acp5, Dcstamp, Oscar and Calcr genes in the osteoclast differentiation pathway of the RANKL group vs the CTL group. C is the expression changes of Ctsk, Acp5, Dcstamp, Oscar and Calcr genes in the osteoclast differentiation pathway of the RANKL+ILA group vs the RANKL group. DETAILED DESCRIPTION

[0023] In the context of this specification, unless otherwise specified, any term used in this specification has the meaning commonly understood by those skilled in the art in the art, and the experimental methods without detailed conditions are carried out according to conventional experimental methods or according to the operating instructions recommended by the supplier. Indole-3-lactic acid (ILA) was purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd. (Cat#BD13033).

[0024] Example 1: ILA can inhibit osteoporosis in mice

[0025] Six-week-old mice were weighed and randomly divided into two groups. One group was injected intraperitoneally with 200 μL cyclophosphamide (CTX, 75 mg / kg) to establish a mouse osteoporosis model, and the other group was injected with an equal volume of saline as a control (CTL group). All the above mice were treated with antibiotics in advance (free drinking water containing four antibiotics, namely 0.2 mg / ml ampicillin, 0.2 mg / ml metronidazole, 0.2 mg neomycin and 0.1 mg / ml vancomycin) for 1 week to eliminate intestinal flora. One week later, the above mice were divided into 3 groups (except the CTL group, the mice injected with cyclophosphamide were randomly divided into two groups: CTX group and CTX+ILA group), namely CTL group, CTX group and CTX+ILA group, and 9 mice were randomly selected from each group. The mice in the CTX+ILA group were gavaged with 200 μL of ILA (20 mg / kg) daily; the CTL group and CTX group were gavaged with an equal volume of saline daily. After 1 month of intervention, serum and femur samples were collected from mice for bone function assessment.

[0026] The detection of ILA content in the femoral bone marrow of mice found that after oral administration of ILA, the level of ILA in the bone marrow increased significantly ( Figure 1A, p<0.0001), indicating that increasing the uptake of ILA can increase the abundance of ILA in the mouse bone marrow. MicroCT examination of the mouse femur showed that compared with the CTX group, the bone mineral density (BMD), bone volume fraction (BV / TV), bone surface area to tissue volume ratio (BS / TV) and trabecular number (Tb.N) of the CTX+ILA group were significantly increased ( Figure 1 At the same time, ILA intervention also alleviated the increase in trabecular bone separation (Tb.Sp) caused by CTX treatment to a certain extent ( Figure 1 E). Subsequently, TRAP staining was used to detect the abundance of osteoclasts in the femur of mice. The results showed that after oral administration of ILA, the abundance of TRAP-positive cells in the femur of mice decreased ( Figure 1 Five samples were randomly selected from each group to perform ELISA test on the level of β-CTX in serum. The results showed that intragastric administration of ILA could significantly inhibit the increase of β-CTX serum level induced by CTX ( Figure 1 The above results show that ILA has a significant improvement effect on osteoporosis in mice.

[0027] Example 2: ILA can inhibit osteoclast differentiation

[0028] Fresh bone marrow was collected from the femur and tibia of C57BL / 6 mice, BMDM cells were isolated and cultured, and the cells were randomly divided into 8 groups: CTL group, RANKL group, RANKL+100μM ILA group, RANKL+200μM ILA group, RANKL+500μM ILA group, RANKL+100μM IPA group, RANKL+200μM IPA group and RANKL+500μM IPA group. Among them, the CTL group used αMEM complete medium containing 30ng / mL M-CSF to culture cells; the RANKL group used αMEM complete medium containing 30ng / mL M-CSF and 100ng / mL RANKL to culture cells; the RANKL+100μM (200μM, 500μM) ILA group used αMEM complete medium supplemented with 30ng / mL M-CSF, 100ng / mL RANKL and different concentrations (100μM, 200μM, 500μM) ILA; the RANKL+100μM (200μM, 500μM) IPA group used αMEM complete medium supplemented with 30ng / mL M-CSF, 100ng / mL RANKL and different concentrations (100μM, 200μM, 500μM) IPA. After inducing osteoclast differentiation for 5 days, cells were stained for TRAP. The results showed that compared with the CTL control group, a large number of BMDM cells in the RANKL group differentiated into osteoclasts ( Figure 2 After adding different concentrations (100 μM, 200 μM and 500 μM) of ILA to treat the cells, it was found that the three concentrations of ILA could significantly inhibit the formation of osteoclasts ( Figure 2 CE). IPA is a downstream metabolite of ILA produced by the indole pathway of tryptophan metabolism. As above, we simultaneously detected the effect of IPA on osteoclast differentiation through in vitro experiments. However, after adding different concentrations (100μM, 200μM and 500μM) of IPA to treat cells, TRAP staining found that the three concentrations of IPA could not inhibit the formation of osteoclasts. The above results show that ILA has a direct inhibitory effect on osteoclast differentiation, and the use of 100μM ILA can play the role of inhibiting osteoclast differentiation.

[0029] Example 3: Overexpression of the ldhA gene can inhibit osteoporosis in mice

[0030] The full-length DNA fragment of the ldhA gene was cloned into the pRSFDuet vector using standard molecular cloning techniques, and then introduced into the Ec bacteria to construct the Ec-ldhA engineered bacteria. 1 mL of the Ec-ldhA engineered bacteria was transferred to 10 mL of MRS liquid sterile culture medium for activation culture for 3 generations at 37°C for 24 hours; then the bacterial solution was inoculated into 200 mL of MRS liquid sterile culture medium at a ratio of 2% and cultured at 37°C for 24 hours. Subsequently, the bacterial solution was centrifuged at 4°C and 3000 r / min for 15 minutes, and the supernatant was discarded to collect the bacteria. The live bacteria were resuspended in PBS buffer (pH = 7.0) and the concentration of the live bacterial suspension was adjusted to 10 9 CFU / 200μL, store at 4℃ for future use. Prepare afresh once a week.

[0031] Six-week-old mice were weighed and randomly divided into two groups. One group was injected intraperitoneally with 200 μL cyclophosphamide (CTX, 75 mg / kg) and the other group was injected with an equal volume of saline as a control (CTL group). All the mice were treated with antibiotics in advance (freely drinking water containing four antibiotics, namely 0.2 mg / ml ampicillin, 0.2 mg / ml metronidazole, 0.2 mg neomycin and 0.1 mg / ml vancomycin) for 1 week to eliminate intestinal flora. One week later, the mice were divided into three groups (except the CTL group, the mice injected with cyclophosphamide were randomly divided into two groups: CTX group and CTX+Ec-ldhA group), namely CTL group, CTX group and CTX+Ec-ldhA group, with 5 mice randomly selected from each group. Mice in the CTX+Ec-ldhA group were gavaged daily with 1×10 9 CFU Ec-ldhA bacteria 200μL; CTX group mice were gavaged daily with 1×10 9CFU Ec bacteria 200μL; the CTL group was gavaged with an equal volume of normal saline daily. After 1 month of intervention, serum and femur samples were collected from mice for bone function assessment.

[0032] Mass spectrometry analysis revealed that after oral administration of Ec-ldhA bacteria, the ILA content in the femoral bone marrow of mice increased, and its abundance was significantly higher than that in the control group (CTL group) and the CTX group ( Figure 3 (A, p<0.001). MicroCT scan results showed that the bone mineral density (BMD) and bone volume fraction (BV / TV) in the CTX+Ec-ldhA group were significantly higher than those in the CTX group ( Figure 3 In addition, the intervention of Ec-ldhA bacteria also alleviated the abnormalities of bone surface area to tissue volume ratio (BS / TV), trabecular number (Tb.N) and trabecular separation (Tb.Sp) caused by CTX to a certain extent ( Figure 3 TRAP staining experiments found that after oral administration of Ec-ldhA bacteria, the abundance of TRAP-positive cells in the femur of mice decreased ( Figure 3 FH in the middle). The ELISA was used to detect the β-CTX content in serum and found that oral administration of Ec-ldhA bacteria could significantly inhibit the increase of β-CTX serum level induced by CTX ( Figure 3 The above results show that ldhA protein can inhibit osteoclast formation by producing ILA and significantly improve osteoporosis.

[0033] Example 4: ILA can inhibit the expression of osteoclast differentiation-related genes

[0034] Fresh bone marrow was collected from the femur and tibia of C57BL / 6 mice, BMDM cells were isolated and cultured, and the cells were randomly divided into 3 groups: CTL group, RANKL group and RANKL+ILA group, with 4 replicates in each group. Among them, the CTL group used αMEM complete medium containing 30ng / mL M-CSF to culture cells; the RANKL group used αMEM complete medium containing 30ng / mL M-CSF and 100ng / mL RANKL to culture cells; the RANKL+ILA group used αMEM complete medium containing 30ng / mL M-CSF, 100ng / mL RANKL and 100μM ILA to culture cells. After inducing osteoclast differentiation for 5 days, the cells were collected and total RNA was extracted for RNA-seq experiments. The results showed that in the comparison between the RANKL+ILA group and the RANKL group, KEGG pathway analysis showed that the osteoclast differentiation pathway was significantly enriched ( Figure 4The detection of differentially expressed genes found that compared with the CTL group, several key genes involved in osteoclast differentiation in the RANKL group (such as Ctsk, Acp5, Dcstamp, Oscar, and Calcr, etc.) were significantly upregulated ( Figure 4 After adding ILA, the expression of genes such as Ctsk, Acp5, Dcstamp, Oscar and Calcr decreased significantly ( Figure 4 The above results indicate that ILA can downregulate the expression of Ctsk, Acp5, Dcstamp, Oscar and Calcr genes, inhibit the osteoclast differentiation pathway, and then inhibit osteoclast differentiation and alleviate osteoporosis.

[0035] The above-mentioned specific implementation methods are used to explain the present invention and are only preferred embodiments of the present invention, rather than limiting the present invention. Any modifications, equivalent substitutions, improvements, etc. made to the present invention within the spirit of the present invention and the protection scope of the claims shall fall within the protection scope of the present invention.

Claims

1. Application of indole-3-lactic acid in the preparation of medicines for preventing or treating osteoporosis.

2. Application of indole-3-lactic acid in the preparation of drugs for improving chemotherapy-induced osteoporosis.

3. Application of indole-3-lactic acid in the preparation of osteoclast inhibitors.

4. Application of engineered bacteria that metabolize and synthesize indole-3-lactic acid in the preparation of drugs for preventing or treating osteoporosis.

5. Application of engineered bacteria that metabolize and synthesize indole-3-lactic acid in the preparation of drugs to improve chemotherapy-induced osteoporosis.

6. Application of engineered bacteria that metabolize and synthesize indole-3-lactic acid in the preparation of osteoclast inhibitors.

7. The use according to any one of claims 4 to 6, characterized in that: The engineered bacteria are Ec-ldhA bacteria, specifically: the full-length DNA fragment of the ldhA gene (SEQ ID NO: 1) is cloned into the pRSFDuet vector using molecular cloning technology, and then introduced into E. coli bacteria to construct the Ec-ldhA engineered bacteria.

8. Any drug or inhibitor for use according to any one of claims 1 to 6, wherein indole-3-lactic acid is the only active ingredient in the drug or inhibitor.

9. The administration method of any drug or inhibitor according to any one of claims 1 to 6 is oral administration.